Skip to content
Peptide research

DS (Asp-Ser)

Category
Brain & Cognition
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

A Khavinson-family dipeptide (aspartic acid, serine) marketed for neuroprotection and healthy brain aging. The case rests on an epigenetic mechanism and animal data; human evidence is speculative, with no clinical trials. No adverse effects are reported, but human safety data for DS itself is essentially absent, and unregulated sourcing raises purity concerns. Not an approved drug in the US; sold only as a research-grade product.

Read Full record

Studied uses & evidence

Studied uses(4)

  • Neuroprotection via epigenetic modulation

    Speculative

    Based on molecular modeling of DS binding histone H1.3, not tested in cells or animals.

  • Calcium homeostasis regulation in neurons

    Speculative

    Inferred from a proposed gene target linked to calcium signaling, not measured directly for DS.

  • Potential Alzheimer's disease-relevant neuroprotection

    Speculative

    Alzheimer's relevance is extrapolated from related peptides in reviews, not from DS-specific studies.

Evidence limits

Evidence Level
Preclinical

Evidence for DS dipeptide is limited to molecular modeling (in silico) studies and broader class-level preclinical data from the Khavinson bioregulator research program. No specific human clinical trials for the DS dipeptide have been published in Western peer-reviewed journals. The parent compound Cortexin has undergone clinical trials in Russia for cerebrovascular disorders and brain injuries.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Risk summary(6)

Risks = level of concern: High · Moderate · Low · Theoretical

  • No specific adverse effects have been reported for DS dipeptide in published literature

    Low
  • Khavinson peptide bioregulators as a class are reported to lack toxic, allergic, or adverse effects in experimental and clinical studies

    Low
  • Very limited safety data specific to DS — most safety data comes from the broader Khavinson peptide class

    Moderate
  • No long-term human safety studies have been conducted for DS specifically

    Moderate
  • As with all research peptides, purity and sourcing are critical concerns; unregulated products may contain contaminants

    High
  • Theoretical risk of unintended epigenetic modifications given the chromatin-modulating mechanism, though not observed in available studies

    Theoretical
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.